A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients

Value in Health

Volumn 10, Issue 3, 2007, Pages 173-182

  Knoester, Pieter D ^a   Deckers, Charles L P ^b   Termeer, Eveline H ^c   Boendermaker, Arjo J ^d   Kotsopoulos, Irene A W ^e   De Krom, Marc C T F M ^e   Keyser, Toine ^c   Renier, Willy O ^c   Hekster, Yechiel A ^c   Severens, Hans L ^d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Decision tree model; Epilepsy; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE CONTROL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; SEIZURE; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 34249087668     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00167.x     Document Type: Article

References (35)

1. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995 345 : 476 9.
2. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996 23 : 149 55.
3. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999 37 : 81 7.
4. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999 40 : 601 7.
5. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000 9 : 375 9.
6. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001 56 : 172 7.
7. Riteco JA, Heij LJM, van Luijn JCF, Wolff I. Richtlijnen voor farmaco-economisch onderzoek. Amstelveen : College voor zorgverzekeringen, 1999 (in Dutch).
8. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000 41 : 1364 74.
9. Deckers CLP. The place of combination therapy in the early treatment of epilepsy. CNS Drugs 2002 16 : 155 63.
10. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York : Oxford University Press, 1997.
11. Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med 2000 51 : 243 9.
12. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen : College voor zorgverzekeringen, 2000 (in Dutch).
13. Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995 52 : 989 96.
14. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997 26 : 451 60.
15. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992 327 : 765 71.
16. Nieto-Barrera M, Brozmanova M, Capovilla G, et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001 46 : 145 55.
17. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994 57 : 682 7.
18. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995 58 : 44 50.
19. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998 51 : 1282 8.
20. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983 33 : 904 10.
21. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982 45 : 55 9.
22. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study Group. Epilepsy Res 1999 34 : 199 205.
23. Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure 2000 9 : 486 92.
24. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 342 : 314 9.
25. Arroyo S, Sander JWAS. Carbamazepine in comparative trials. Pharmacokinetic characteristics too often forgotten. Neurology 1999 53 : 1170 4.
26. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002 43 (Suppl. 4 10 16.
27. Hakkarainen H. Carbamazepine vs. diphenylhydantoin vs. their combination in adult epilepsy. Neurology 1980 30 : 354.
28. Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996 25 : 257 62.
29. Ramsey SD, Sullivan SD. Weighing the economic evidence: guidelines for critical assessment of cost-effectiveness analyses. J Am Board Pract 1999 12 : 477 85.
30. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000 53 : 688 95.
31. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002 43 (Suppl. 4 3 9.
32. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998 39 (Suppl. 3 S19 25.
33. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998 7 : 119 25.
34. National Institute for Clinical Excellence. Newer Drugs for Epilepsy. 2004. Available from: http://www.nice.org.uk/TA076guidance [Accessed March 1, 2005].
35. Holloway RG, Ringel SP, Bernat JL, et al. US neurologists: attitudes on rationing. Neurology 2000 55 : 1492 7.